Navigation Links
Actinium Pharmaceuticals Appoints Kaushik J. Dave, Ph.D., MBA As President, Chief Executive Officer And Director
Date:9/16/2013

NEW YORK, Sept. 16, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing  innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the appointment of Kaushik J. Dave, Ph.D., MBA., to the position of President and Chief Executive Officer effective September 16, 2013.  Dr. Dave also joined the Board of Directors of Actinium.  Dr. Dave has nearly 25 years of broad biotech and pharmaceutical experience at both large and emerging growth biopharmaceutical companies.  Concurrently with Dr. Dave's appointment, Mr. Sergio Traversa resigned from the positions of Interim President and Interim Chief Executive Officer of Actinium Pharmaceuticals, Inc., effective immediately.  Mr. Traversa remains as a Director and Interim Chief Financial Officer of the Company.

A message released by the Board of Directors stated, "We are very pleased to add Kaushik's strategic biologics product development and business development experience to the Actinium team.  Kaushik brings to Actinium a proven track record of successful product development through FDA approval and his extensive background in strategic program management will be extremely valuable to us as we move our clinical pipeline towards approval.  We look forward to working closely with Kaushik in progressing Actinium's lead candidates Iomab-B and Actimab-A and together realizing the potential of Actinium's technology platform."

"It's an exciting time to join the Actinium organization," said Dr. Dave.  "Actinium's pipeline and work to date has been impressive; I look forward to further advancing the Company's robust product pipeline and business strategy.  Most exciting is preparing for the pivotal trial for Iomab-B, a bone marrow conditioning regimen which can significantly improve survival outcomes in the most severe patients afflicted with Acute Myeloid Leukemia or AML and the Phase I/II trial for Actimab-A as an induction therapy for AML.  Based on my depth of experience, I expect to make significant contributions leading Actinium's ongoing product and business development activities and also toward building a company that is well-positioned to capitalize on the expected demand for Iomab-B and Actimab-A and to realize the potential of its technology platform."

Dr. Dave joins Actinium Pharmaceuticals from Antares Pharmaceuticals Inc. where he was the Executive Vice President of Product Development.  As part of the core leadership team at Antares, he was instrumental in setting strategy, vision, product portfolio development and business development for that company over the past several years.  Dr. Dave led the clinical and regulatory approval of Anturol™ and was also a key contributor to the change in company vision to combination products using Antares' medical device technology which resulted in a robust pipeline that included development and New Drug Application submission for Otrexup which as an October 14, 2013 PDUFA date.  As a result of these efforts, Antares Pharma grew from a market capitalization of $40 million to about a half billion during his tenure.  Prior to Antares, Dr. Dave was Vice President Product Development at Palatin Technologies Inc. where he obtained approval of NeutroSpec™ (a radiopharmaceutical monoclonal antibody product).  Prior to Palatin, Dr. Dave was employed at Schering-Plough Inc. and Merck & Co. Inc. responsible for steering the development of several pharmaceutical product development programs.  Dr. Dave received his pharmacy degree from the University of Bath, UK and a Ph.D. in Pharmaceutical Chemistry from the University of Kansas.  Dr. Dave also received an MBA from the Wharton School of the University of Pennsylvania.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) is a New York based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers.  Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha emitting actinium-225 and bismuth-213 radiopharmaceuticals in conjunction with monoclonal antibodies.  The Company also develops other radiopharmaceuticals for select applications.

For more information:
Visit our web site www.actiniumpharmaceuticals.com

Contact:
Media:
Dennis S. Dobson Jr. of Dennis S. Dobson Inc.
Tel:  (203) 258-0159
Email: dsdobson@optonline.com
www.dobsonmediagroup.com

Actinium Pharmaceuticals, Inc.
Investor/Media Relations: Corey Sohmer, (646) 459-4201
E-mail: ir@actiniumpharmaceuticals.com

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actinium Pharmaceuticals Clinical Results Featured at a United Nations Forum
2. Actinium Pharmaceuticals, Inc. Receives $3.5m from Exercise of Warrants
3. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
4. Actinium Pharmaceuticals, Inc. Receives Notice of Patent Allowance for a Key Application
5. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
6. Actinium Pharmaceuticals, Inc. To Present at the 15th Annual BIO CEO Investor Conference
7. Actinium Pharmaceuticals to Present at EMIT Targeted Radiotherapy Conference
8. University of Pennsylvania joins Actinium Pharmaceuticals Multicenter Actimab-A Trial
9. Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
10. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
11. Actinium Pharmaceuticals Announces New Round of Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)...  Caris Life Sciences ® , a leading innovator ... precision medicine, today announced that St. Jude Medical Center,s ... (POA) as its 17 th member. Through participation ... Cancer Institute will help develop standards of care and ... making cancer treatment more precise and effective. ...
(Date:10/10/2017)... EXTON, Pa. , Oct. 10, 2017   ... leader in innovative solutions for injectable drug administration, today ... of West,s ID Adapter for improving the intradermal administration ... the Fourth Skin Vaccination Summit in May 2017 by ... Team Lead, Polio Department, World Health Organization (WHO), and ...
(Date:10/4/2017)... , Oct. 4, 2017  According to the Centers for Disease ... end of October . PhysicianOne Urgent Care is helping communities across ... Westchester, NY , by offering no-cost* flu shots through the end ... mandated by certain health insurance regulations. ... The best time to get a flu shot is by the end ...
Breaking Medicine Technology:
(Date:10/13/2017)... New York, NY (PRWEB) , ... October 13, 2017 , ... ... most influential people in business to advocate for action towards gender equality at their ... 18,000 views from around the globe, and reached a social audience of over 3 ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, ... lowdown on sciatica in a new episode of "Success Files," which is an ... and innovation and investigates each subject in-depth with passion and integrity. , Sciatica ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of ... Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, ... In honor of Morris F. Collen, a pioneer in the field of medical informatics, ...
Breaking Medicine News(10 mins):